Printer Friendly

AFFINITY BIOTECH APPOINTS NEW DIRECTOR OF PHARMACOLOGY

 AFFINITY BIOTECH APPOINTS NEW DIRECTOR OF PHARMACOLOGY
 BOOTHWYN, Pa., Nov. 13 /PRNewswire/ -- Affinity Biotech, Inc. (NASDAQ: AFBI) today announced that it has appointed Susan T. Nielsen, Ph.D., to the newly created position of director of pharmacology.
 Dr. Nielsen, who received a Ph.D. in pharmacology from the University of Rochester School of Medicine and Dentistry, has more than 10 years experience in laboratory and research management. She has worked with in vivo and in vitro models in several therapeutic areas, including gastrointestinal pharmacology, inflammatory diseases, bone metabolism, and endocrine biochemistry. Previously, Dr. Nielsen spent six years at Wyeth-Ayerst, a division of American Home Products Corporation, where she was a manager of the gastrointestinal pharmacology section and later a manager of the immunology subdivision. Before joining Wyeth, Dr. Nielsen was a research pharmacologist with ICI Americas/Stuart Pharmaceuticals. She is the author of 28 scholarly publications. As Affinity's director of pharmacology, she will supervise the company's animal studies of its microemulsion drug delivery and synthetic blood formulations.
 "Our ability to design and implement preclinical studies in protein drug delivery, both for Affinity's proprietary therapeutics and those of our corporate partners, is enhanced greatly by the addition of Dr. Nielsen to our company," said Alan F. Dickason, Ph.D., CEO of Affinity. "Her experience advancing drugs from the preclinical stage to the clinic will be very valuable to Affinity as we move toward IND filings on compounds using our microemulsion delivery system."
 Based in Boothwyn, Affinity Biotech focuses on the development of oral drug delivery systems for proteins and other therapeutic agents, taste masking of therapeutic agents, the development of synthetic blood and other microemulsion-based pharmaceutical products.
 -0- 11/13/92
 /CONTACT: Alan F. Dickason, president and CEO of Affinity Biotech, Inc., 215-497-0500, or Anthony J. Russo or Kathryn Comba of Noonan/Russo Communications, 212-979-9180, for Affinity Biotech, Inc./
 (AFBI) CO: Affinity Biotech, Inc. ST: Pennsylvania IN: MTC SU: PER


TS-PS -- NY017 -- 0585 11/13/92 10:01 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 13, 1992
Words:328
Previous Article:ROYAL CARIBBEAN INTRODUCING VEGETARIAN MENUS
Next Article:COKE CONSOLIDATED BOARD DECLARES FOURTH QUARTER DIVIDEND
Topics:


Related Articles
From Basic Science to New Cancer Therapies: Synergies in Innovation, Translational Research, and Business Growth; William Hait, MD, PhD to Discuss...

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters